Overactive bladder could be a medical syndrome, outlined by urinary incontinence typically characterised by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are thought-about because the initial line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are a number of the generic drugs used for the treatment of overactive bladder. These medicine acts by antagonizing cholinergic receptors that has the relief from the frequent urination.
How Big is The Global Overactive Bladder Treatment Market?
The Overactive Bladder Treatment Market is expected to be around US$ 4.90 Billion by 2028 at a CAGR of 2.5% in the given forecast period.
The major driving factors of Overactive Bladder Treatment Market are as follows:
The major restraints factors of Overactive Bladder Treatment Market are as follows:
The Overactive Bladder Treatment Market has been segmented as below:
By Therapy Type:
By Disease:
By Regional Analysis:
The Overactive Bladder Treatment Market is segmented on the lines of its therapy, disease and regional. Based on therapy it covers Anticholinergics, Solifenacin, Oxybutynin, Darifenacin, Fesoterodine, Tolterodine, Trospium, Other Anticholinergics, Mirabegron, BOTOX and Neurostimulation. Based on disease type it covers Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity. The Overactive Bladder Treatment Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for Overactive Bladder Treatment Market and related technologies.
2) Analyses of global market trends, with data from 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2028.
3) Identifications of new market opportunities and targeted promotional plans for Overactive Bladder Treatment Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
Report Scope:
The scope of the report includes a detailed study of Overactive Bladder Treatment Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report Astellas Pharma Inc, Pfizer, Inc, Teva Pharmaceutical Industries Limited, Allergan, PLC, Mylan N.V, Endo International PLC, Hisamitsu Pharmaceutical Co., Inc, Sanofi, Aurobindo Pharma Limited, Johnson & Johnson, Intas Pharmaceuticals Ltd, Apotex Inc, Macleods Pharmaceuticals Ltd and Medtronic PLC. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
Reasons to Buy this Report:
1) Obtain the most up to date information available on all Overactive Bladder Treatment Market.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Overactive Bladder Treatment Market.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our new reports:
Parkinson’s Disease Treatment Market
Veterinary Surgical Instruments Market
1. Introduction
1.1 Key Findings
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Data
2.2 Market Size Estimation and Data Triangulation
2.3 Research Assumptions
3. Summary with Insights
4. Market Overview
4.1 Introduction
4.2 Drivers
4.3 Restraints
4.4 Industry Trends
4.5 Porter’s Five Forces Analysis
5. Overactive Bladder Treatment Market Analysis, By Therapy
5.1 Anticholinergics
5.2 Solifenacin
5.3 Oxybutynin
5.4 Darifenacin
5.5 Fesoterodine
5.6 Tolterodine
5.7 Trospium
5.8 Other Anticholinergics*
5.9 Mirabegron
5.10 BOTOX
5.11 Neurostimulation
6. Overactive Bladder Treatment Market Analysis, By Disease
6.1 Idiopathic Bladder Overactivity
6.2 Neurogenic Bladder Overactivity
7. Overactive Bladder Treatment Market Analysis, By Region
7.1 North America
7.2 Europe
7.3 Asia-Pacific
7.4 Rest of the World
8. Competitive Overview
8.1 Introduction
8.2 New Product Launches
8.3 Acquisitions
8.4 Agreements, Partnerships, And Collaborations
8.5 Expansions
9. Company Profiles
9.1 Mylan N.V.
9.2 Endo International PLC
9.3 Macleods Pharmaceuticals Ltd.
9.4 Astellas Pharma Inc.
9.5 Hisamitsu Pharmaceutical Co., Inc.
9.6 Sanofi
9.7 Apotex Inc.
9.8 Pfizer, Inc.
9.9 Teva Pharmaceutical Industries Limited
9.10 Allergan, PLC.
9.11 Aurobindo Pharma Limited
9.12 Johnson & Johnson
9.13 Intas Pharmaceuticals Ltd.
9.14 Medtronic PLC
The Overactive Bladder Treatment Market has been segmented as below:
By Therapy Type:
By Disease:
By Regional Analysis:
